Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRTX - Mirati Therapeutics, Inc.

Close
58.7
-0.100   -0.170%

Share volume: 0
Last Updated: Mon 22 Jan 2024 10:00:00 PM CET
Pharmaceutical Preparation Manufacturing : 2.38%

PREVIOUS CLOSE
CHG
CHG%
$58.80
-0.10
-0.17%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 18%
Dept financing 4%
Liquidity 75%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$58.70
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$12.15
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
70.148 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: David D. Meek
Region: US
Website: mirati.com
Employees: 590
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers. Sitravatinib, an investigational spectrum-selective kinase inhibitor, is in clinical trials for the treatment of NSCL cancer.

Recent news